Tom 13, Nr 4 (2016)
Artykuł przeglądowy
Opublikowany online: 2016-12-20
Wyświetlenia strony
2272
Wyświetlenia/pobrania artykułu
23100
Choroba Alzheimera — nowe strategie leczenia
Psychiatria 2016;13(4):210-214.
Streszczenie
Choroba Alzheimera (AD) jest neurodegeneracyjna i stanowi główną przyczynę otępienia u osób starszych. Jej podłoże jest wieloczynnikowe, uważa się jednak, że główny mechanizm jej rozwoju stanowi odkładanie się ß-amyloidu i fosforyzowanego białka tau w tkance mózgowej. Obecnie AD jest nieuleczalna. Dostępna farmakoterapia jedynie łagodzi objawy. Z tego powodu prowadzone są intensywne prace nad wynalezieniem leczenia przyczynowego. Obecne prace skupiają się na immunoterapii oraz na elemininacji nadmiaru ß-amyloidu z organizmu.
Słowa kluczowe: choroba Alzheimeraotępieniebeta-amyloidbiałko tauimmunoterapia
Referencje
- Gelinas DS, DaSilva K, Fenili D, et al. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2: 14657–14662.
- Folch J, Petrov D, Ettcheto M, et al. Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plast. 2016; 2016: 8501693.
- Korolev IO. Alzheimer’s disease: a clinical and basic science review. Medical Student Research Journal . 2014; 4: 24–33.
- Fu HJ, Liu B, Frost JL, et al. Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010; 9(2): 197–206.
- Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med. 2010; 220(2): 95–106.
- Cribbs DH. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets. 2010; 9(2): 207–216.
- Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008; 15(4): 555–569.
- Valera E, Spencer B, Masliah E. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics. 2016; 13(1): 179–189.
- Farlow MR, Andreasen N, Riviere ME, et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1): 23.
- Andreasen N, Simeoni M, Ostlund H, et al. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. PLoS One. 2015; 10(3): e0098153.
- Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses. 2004; 63(1): 8–20.
- Doody RS, Gavrilova SI, Sano M, et al. dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008; 372(9634): 207–215.
- Pieper AA, Xie S, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010; 142(1): 39–51.
- Steele JW, Lachenmayer ML, Ju S, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry. 2013; 18(8): 889–897.
- Yamashita M, Nonaka T, Arai T, et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. 2009; 583(14): 2419–2424.
- Doody RS, Gavrilova SI, Sano M, et al. dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008; 372(9634): 207–215.
- Doody R, Winblad B, Cummings J, et al. Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials. Alzheimer's & Dementia. 2012; 8 (4 supl. 1): P456.
- Chau S, Herrmann N, Ruthirakuhan MT, et al. Latrepirdine for Alzheimer's disease. Cochrane Database Syst Rev. 2015(4): CD009524.
- Cano-Cuenca N, Solís-García del Pozo JE, Jordán J. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. J Alzheimers Dis. 2014; 38(1): 155–164.
- Burns J, Yokota T, Ashihara H, et al. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002; 50(11): 3337–3340.
- Rimando AM, Kalt W, Magee JB, et al. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem. 2004; 52(15): 4713–4719.
- Sanders TH, McMichael RW, Hendrix KW. Occurrence of resveratrol in edible peanuts. J Agric Food Chem. 2000; 48(4): 1243–1246.
- Orgogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris). 1997; 153(3): 185–192.
- Krikorian R, Nash TA, Shidler MD, et al. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr. 2010; 103(5): 730–734.
- Abraham J, Johnson RW. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res. 2009; 12(6): 445–453.
- Turner RS, Thomas RG, Craft S, et al. Alzheimer's Disease Cooperative Study. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015; 85(16): 1383–1391.
- Abd El-Mohsen M, Bayele H, Kuhnle G, et al. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br J Nutr. 2006; 96(1): 62–70.
- Ho DJ, Calingasan NY, Wille E, et al. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol. 2010; 225(1): 74–84.
- Whitfield JF. The road to LOAD: late-onset Alzheimer's disease and a possible way to block it. Expert Opin Ther Targets. 2007; 11(10): 1257–1260.
- Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007; 69(9): 878–885.
- Reed B, Villeneuve S, Mack W, et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014; 71(2): 195–200.
- Williams PT. Lower risk of Alzheimer's disease mortality with exercise, statin, and fruit intake. J Alzheimers Dis. 2015; 44(4): 1121–1129.
- Lin FC, Chuang YS, Hsieh HM, et al. Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study. Medicine (Baltimore). 2015; 94(47): e2143.
- Tamaoka A. [Dyslipidemia and Dementia]. Brain Nerve. 2016; 68(7): 737–742.
- Doody RS, Raman R, Sperling RA, et al. Alzheimer’s Disease Cooperative Study. Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1): 36.
- Green RC, Schneider LS, Amato DA, et al. Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009; 302(23): 2557–2564.
- Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis. 2015; 44(2): 705–720.
- Bulic B, Pickhardt M, Schmidt B, et al. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl. 2009; 48(10): 1740–1752.
- Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009; 73(10): 768–774.
- Holmes C, Cunningham C, Zotova E, et al. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology. 2011; 77(3): 212–218.
- Butchart J, Brook L, Hopkins V, et al. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015; 84(21): 2161–2168.
- Hirsh S, Huber L, Stein R, et al. Open label, crossover, pilot study to assess the efficacy and safety of perispinal administration of etanercept (Enbrel ® ) in combination with nutritional supplements versus nutritional supplements alone in subjects with mild to moderate Alzheimer’s disease receiving standard care. FASEB J . 2016; 30: lb296.
- Ohyagi Y. Apomorphine: A Novel Efficacy for Alzheimer?s Disease and Its Mechanisms. Journal of Alzheimer’s Disease & Parkinsonism. 2012; 2(4): e122.
- Martin C, Solís L, Concha MI, et al. [Herpes simplex virus type 1 as risk factor associated to Alzheimer disease]. Rev Med Chil. 2011; 139(6): 779–786.
- Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol. 2009; 217(1): 131–138.
